On Monday, August 31, 2026, the FDA opened a public comment period tied to how compounding pharmacies register and what fees they pay under the Federal Food, Drug, and Cosmetic Act. This matters if you have relied on a compounded version of a GLP-1 medication, whether for cost reasons or because a brand-name product was hard to find. Registration and fee rules shape which pharmacies can legally operate as outsourcing facilities. That, in turn, affects what is available to you and at what price.

The FDA is asking for input on registration requirements and associated fees for outsourcing facilities that compound human drugs, which includes some pharmacies producing compounded GLP-1 products. This is a formal step in the rulemaking process, meaning the agency wants comment before it finalizes how these facilities register and what they owe. If the rules tighten registration standards or raise fees, smaller compounding pharmacies may find it harder to stay in business, which could reduce the number of compounded options on the market. On the other hand, clearer registration rules may help the FDA track which facilities are operating and hold them to consistent standards. The comment period gives pharmacies, patients, and other stakeholders a chance to weigh in before any changes take effect.

This is a proposed collection of information, not a final rule, so nothing changes for you immediately. If you currently use a compounded GLP-1 product, it is reasonable to keep an eye on how this comment period develops, since the outcome could affect which pharmacies remain available to you and what they charge. I would suggest checking in periodically with your pharmacy or prescriber about the source of your medication, particularly if you notice changes in availability or price over the coming months.

Key details

• The FDA is gathering public input on registration rules and fees for compounding…

Originally published on GLP1Laws

Illinois lawmakers are considering a bill that could change how workers' compensation plans handle compounded drugs, including compounded GLP-1 medications. If you rely on workers' comp coverage after a workplace injury, this matters because it could affect which treatments your plan will pay for. The bill was tracked on Wednesday, August 19, 2026, as part of ongoing legislative activity around GLP-1 access. It has not passed yet, but it is worth watching.

The bill, known as HB 1256, would restrict what compounded drugs Illinois workers' compensation plans can reimburse. Compounded GLP-1s are often used as a lower-cost alternative to brand-name versions, so a restriction like this could remove that option for injured workers who currently rely on it. The proposal does not target GLP-1 medications by name. Instead, it applies to compounded drugs more broadly, which means the effect on GLP-1 access would be a side effect of a wider policy change rather than the main goal. Workers who currently use compounded GLP-1s through their workers' comp plan may want to pay attention to how this bill moves through the legislature, since a shift in reimbursement rules could mean higher out-of-pocket costs or a need to switch treatments.

If you are an Illinois worker currently using a compounded GLP-1 medication through workers' compensation, I would suggest keeping an eye on this bill as it moves through the state legislature. It has not become law yet, and the details of how it would be implemented could still change. Talking with your employer's workers' comp administrator or your prescribing provider now may help you understand what your options would be if the bill passes. We will continue tracking this bill and will update this record as new developments occur.

Key details

• Illinois lawmakers are weighing a bill that could stop workers' comp plans from covering…

Originally published on GLP1Laws

On Thursday, August 13, 2026, Eli Lilly filed four separate lawsuits against companies involved in selling peptides or compounded GLP-1 products. All four target parts of the compounded and gray-market supply chain that many patients turn to when brand-name drugs are hard to find or too expensive. If Lilly prevails in these cases, some of the sources people currently use to get these medications could become harder to reach. The cases are early, but together they signal a broader push against this market.

The case against Legendary Peptides appears to target copycat or compounded versions of Lilly's drugs, though the public filing does not yet spell out the specific allegations. Compounded and copycat products have become a common way for patients to access GLP-1 medications when the brand-name versions are unavailable or unaffordable. Because details are limited at this stage, it is not yet clear how broad the claims are or which specific products are involved. Patients who rely on similar products from other sellers may want to watch how this case develops, since it could set an early tone for how Lilly approaches these lawsuits going forward.

Lone Star Peptide Co. sells peptides that fall into the same gray-market category many patients have used to get GLP-1 medications outside the traditional pharmacy system. These products often exist because demand for brand-name drugs has outpaced supply, and buyers have looked for other ways to get similar compounds. A ruling against the company could reduce the number of gray-market options available, which would affect people who have come to depend on them. The outcome here matters less for its details right now and more for what it signals about how aggressively Lilly plans to pursue sellers in this space.

Striker Pharmacy is a compounding pharmacy, which places it in a different position than a peptide seller, since compounding pharmacies are generally allowed to prepare medications under certain regulatory conditions. If Lilly wins this case, it could limit what compounding pharmacies are permitted to produce or sell when it comes to GLP-1 drugs. That would directly affect patients who use compounded versions prescribed through a pharmacy rather than purchased through less regulated channels. The result may take time to unfold, but it is worth tracking, since compounding pharmacies serve as a more regulated alternative to the broader gray market.

Texas Peptides Inc. supplies the raw ingredients used in compounded GLP-1 products, which places this case further upstream in the supply chain than the others. A win for Lilly here could shrink the pool of compounded ingredients available to pharmacies and manufacturers who rely on suppliers like this one. That kind of restriction would ripple outward, potentially affecting multiple compounding pharmacies rather than a single seller. Because ingredient supply sits at the foundation of the compounded drug market, this case may end up having a wider reach than the others, even though it targets just one supplier.

None of these four cases has reached a resolution yet, and the outcomes will likely take months to play out. Readers who currently use compounded or gray-market GLP-1 products may want to keep an eye on how these lawsuits proceed, since the results could affect what is available and from whom. It may also help to talk with a pharmacist or prescriber about how dependent your current access is on these kinds of sources, so you are not caught off guard if the market shifts. This is a legal and regulatory matter, not a medical one, so any decisions about your treatment should go through your own healthcare provider.

Key details

• This lawsuit likely targets copycat or compounded versions of Lilly's drugs.

• Lilly's suit against a peptide seller could affect access to gray-market GLP-1 products.

• A lawsuit against a compounding pharmacy could limit access if Lilly wins.

• This suit against a Texas peptide supplier could shrink the compounded ingredient supply.

Originally published on GLP1Laws

On Tuesday, August 11, 2026, two new lawsuits from Eli Lilly moved through the courts, both aimed at protecting its GLP-1 medications from competition. For patients who rely on these drugs, court fights like these can shape how soon lower cost alternatives reach pharmacy shelves. When a brand name manufacturer challenges a generic maker, the outcome often determines pricing and availability for years to come. This matters most to anyone currently paying out of pocket for a GLP-1 prescription.

Eli Lilly's case against MSN Laboratories centers on a patent dispute meant to keep a lower cost version of its GLP-1 drug off the market. Lawsuits of this kind are common when a brand name company sees a generic filing that could undercut its pricing before patent protections expire. If Lilly succeeds, the timeline for a cheaper option could be pushed back, which would leave patients paying current list prices longer. If MSN prevails or reaches a settlement, a generic version could reach the market sooner, giving patients and insurers a lower cost path to the same treatment. The case is still working through the courts, so no outcome has been decided yet.

The second lawsuit, against Rio Biopharmaceuticals, raises similar questions but offers far less information at this stage. Court filings have not yet disclosed what claims Lilly is making or what product from Rio is at issue. This lack of detail makes it hard to say whether the dispute involves a similar patent challenge or a different kind of conflict altogether. Readers who want to understand how this case might affect access to GLP-1 medications will need to wait for more of the record to become public.

If you take one thing from these filings, let it be that access to GLP-1 medications is being decided as much in courtrooms as in pharmacies. I would suggest keeping an eye on how each case develops, since a ruling against Lilly could open the door to lower cost alternatives sooner than expected. If cost is part of what is keeping you from starting or continuing a GLP-1 medication, it may be worth asking your prescriber or pharmacist whether any lower cost options already exist, since these legal disputes can change what is available from one year to the next.

Key details

• Eli Lilly is suing generic maker MSN Laboratories to block a cheaper GLP-1 version.

• A second Lilly lawsuit targets Rio Biopharmaceuticals, with details not yet public.

Originally published on GLP1Laws

On Wednesday, August 5, 2026, five separate lawsuits against Novo Nordisk moved through the courts, though none of them have revealed their specific claims yet. If you take a GLP-1 medication made by this company, ongoing litigation can eventually shape how that drug is marketed, labeled, or made available to patients. Right now, the details behind these cases remain sealed or simply have not been filed with the court, so the practical effect on patients is still unknown. This record will get updated as those details surface.

Parsley v. Novo Nordisk Inc. sits in a category of case that has, in the past, shaped how manufacturers describe risks, set prices, or make drugs available in certain markets. When a company faces litigation tied to a specific product, it sometimes responds by adjusting language on packaging, tightening supply in certain regions, or changing how it works with insurers and pharmacies while the case moves forward. None of those responses are guaranteed here, and Novo Nordisk has not indicated any change in practice. Still, if you rely on a Novo Nordisk GLP-1 medication, this is the kind of case worth watching, since its outcome could eventually touch the version of the drug you get or how your provider is able to prescribe it.

The Pesole lawsuit against Novo Nordisk remains open even though nothing about its underlying claims has reached the public record. Cases like this can sit unresolved for months, since court filings are sometimes sealed early on while attorneys exchange information or negotiate what becomes public. That silence does not mean the case lacks weight, but it does mean patients and providers have little to act on for now. Once claims are unsealed or amended complaints are filed, the details, and what they mean for people taking this medication, should become clearer.

Ransome v. Novo Nordisk A/S is a newer addition to the group of active cases against the company, and its claims have not yet surfaced publicly. Because it names Novo Nordisk A/S, the parent entity based in Denmark, rather than the U.S. subsidiary named in some other cases, it may eventually raise questions separate from those in domestic filings. For now, there is no way to know whether this case concerns a specific drug, a marketing practice, or something else entirely. Patients taking a GLP-1 medication from Novo Nordisk do not need to take any action based on this filing alone, though it is one more data point in a growing set of legal actions against the company.

Antoury v. Novo Nordisk Inc. has advanced into active court proceedings, which is a step beyond simply being filed, though the underlying details remain sealed. Reaching this stage typically means a judge has accepted the case for further action, even if the public cannot yet see what is being argued. Sealed proceedings are not unusual in early stages of litigation involving pharmaceutical companies, particularly when parties are still working out procedural matters. For patients, this means the case is real and moving, but there is nothing concrete yet to connect to how a specific medication is prescribed or sold.

Malcolm v. Novo Nordisk Inc. is also proceeding through the courts without any public claims attached to it yet. Like the other cases filed this week, its significance for patients will depend entirely on what eventually becomes public, whether that is a product liability claim, a marketing dispute, or something related to pricing. Until then, the case adds to a broader pattern of legal activity surrounding this manufacturer, even if no single filing yet points to a clear outcome for people using its medications. It may be several weeks or months before enough detail emerges to say what, if anything, this means for access to the drug.

None of these five cases have produced enough public detail to change how you use or access a Novo Nordisk GLP-1 medication today. Still, the number of active lawsuits against one manufacturer is worth keeping in view, since legal pressure of this kind can, over time, influence pricing, labeling, or availability even before a single case reaches resolution. If you take one of these medications, I would suggest talking with your provider about any changes to your prescription rather than relying on court filings alone, since those details are not yet available. We will continue tracking each of these cases and update this record as their claims become public.

Key details

• Parsley v. Novo Nordisk Inc. could affect how this drug is marketed or sold.

• The Pesole lawsuit against Novo Nordisk has no public claims yet, but stays active.

• Ransome v. Novo Nordisk A/S is a new case with claims not yet public.

• Antoury v. Novo Nordisk Inc. is now in court, with details still sealed.

• Malcolm v. Novo Nordisk Inc. is proceeding, but its claims are not public yet.

Originally published on GLP1Laws

On August 4, 2026, two separate lawsuits against Novo Nordisk moved forward while federal adverse event data offered a fuller picture of reported side effects across GLP-1 drugs. Neither lawsuit has resulted in any legal finding, and the adverse event reports do not prove a drug caused a given problem. Still, both threads give patients real information to bring into a conversation with their doctor. Here is what the numbers and the litigation actually show today.

The Antoury case is currently active in court, but the lawsuit itself does not establish that Novo Nordisk's drugs caused the harm the plaintiffs describe. A complaint lays out one side's allegations, and it takes discovery, motions, and often a trial before a court reaches any conclusion about what actually happened. That process typically unfolds over months or years, so patients should not expect a quick resolution. In the meantime, the absence of a ruling means the case has not changed anything about how these medications are prescribed or labeled. Patients who want to understand their own risk are better served by looking at the adverse event data reported below and discussing it with their doctor than by tracking the lawsuit's progress.

Malcolm v. Novo Nordisk raises similar concerns about undisclosed risks, but the court filings that would explain exactly what the plaintiffs allege remain sealed. Without access to those details, it isn't possible to say which side effects the case addresses or how the plaintiffs believe the company fell short of its disclosure obligations. Sealed filings are common in early litigation, and they may become public as the case moves forward. Until then, this case remains a pending claim alongside Antoury rather than a confirmed finding, and patients should treat it the same way: worth watching, but not something to act on yet.

Zepbound recorded 6,772 reports of severe nausea, vomiting, or dehydration over the past year, the highest count among the seven GLP-1 drugs tracked in the FAERS database. This number comes from the FDA's Adverse Event Reporting System, which collects reports voluntarily submitted by patients, doctors, and manufacturers, so it reflects how many reports were filed rather than a confirmed rate of how often the side effect occurs. A higher report count can also reflect how widely a drug is prescribed, since more prescriptions generally lead to more reports. Even so, the size of this number makes it a reasonable topic to raise with your doctor, especially if you are currently taking Zepbound or considering it. Bringing your own experience with nausea or dehydration into that conversation will give your doctor more useful information than the raw count alone.

Ozempic logged 779 reports of NAION, a form of vision loss, over the past year, more than any other GLP-1 drug in the FAERS data reviewed here. As with the nausea reports, this figure reflects the number of reports submitted, not a confirmed link between Ozempic and vision loss, and FAERS data cannot establish that the drug caused any individual case. Still, a report count this size is worth raising directly with your doctor, particularly if you have noticed any changes in your vision while taking Ozempic. Your doctor can weigh this alongside your full medical history in a way that a database total cannot.

Mounjaro had 3,643 reports of severe nausea, vomiting, or dehydration over the past year, placing it behind Zepbound but well ahead of several other GLP-1 drugs in the same category. Comparing these totals across drugs can be useful, but it also has limits, since drugs with more prescriptions written will tend to generate more reports regardless of how safe they are relative to one another. If you are taking Mounjaro and have experienced ongoing nausea or signs of dehydration, that combination of symptoms is worth describing to your doctor in detail rather than assuming it is a known and expected side effect. Your doctor can help determine whether your symptoms need attention beyond what you might manage on your own.

None of the numbers or lawsuits described here amount to medical advice, and none of them should lead you to stop or change a GLP-1 medication on your own. What they do offer is a starting point for a more specific conversation with your doctor, whether that means asking about your own risk of severe nausea, mentioning any vision changes you've noticed, or simply asking how your prescriber weighs FAERS data when monitoring patients on these drugs. The two lawsuits against Novo Nordisk are worth watching as they develop, particularly if the sealed details in the Malcolm case become public, but they have not changed what is known or approved today. The most useful step available to you right now is to bring this information into your next appointment rather than waiting for a court to reach a conclusion.

Key details

• Antoury v. Novo Nordisk claims are unproven, so no side effect finding exists yet.

• Malcolm v. Novo Nordisk also alleges hidden risks, but details stay sealed.

• Zepbound had the highest severe nausea report count, 6,772, among tracked drugs.

• Ozempic logged 779 vision loss reports, a signal worth discussing with your doctor.

• Mounjaro had 3,643 severe nausea and dehydration reports over the past year.

Originally published on GLP1Laws

News coverage often frames lower-cost GLP-1s as a story about compounding pharmacies, but the real timeline runs through patent law and a handful of older statutes that shape drug pricing and access. Understanding those statutes tells you more about when a cheaper GLP-1 might reach you than any compounding headline. For someone paying cash today, that distinction changes what to watch for, and what to do while waiting.

Before any generic or biosimilar pathway could exist, the FDA needed a system for approving the original drug in the first place, and that system dates back to the Federal Food, Drug, and Cosmetic Act of 1938. That law built the premarket review process the FDA still uses today, requiring a drug to prove its safety before it can reach a pharmacy shelf. Later laws, including the ones that created the generic and biosimilar pathways, all sit on top of this foundation. Without the review system the FDCA established, there would be no approved brand drug to copy, and no equivalence standard for a generic maker to meet. That is why the patent clock described in this series only makes sense once you understand the review system it depends on.

Getting a lower-cost GLP-1 will still mean picking up the phone to your doctor's office, a requirement that traces back to the Durham-Humphrey Amendment of 1951. That amendment made GLP-1 drugs, along with many others, available only by prescription, which means a pharmacist cannot dispense one without a doctor's order. This matters for the cost conversation because price is only one part of the picture. Even after a lower-cost version arrives once patents lapse, a patient will still need a prescription to get it, which keeps a physician involved in the decision. That requirement predates GLP-1s by decades, but it applies to every version of these drugs, brand or generic, once available.

For patients on Medicaid, a lower price does not have to wait on any patent expiring, thanks to a rebate system set up by the Omnibus Budget Reconciliation Act of 1990. That law created the Medicaid Drug Rebate Program, in which manufacturers agree to rebates in exchange for having their drugs covered under Medicaid. For patients enrolled in that program, this rebate arrangement can lower the cost of a GLP-1 today, regardless of whether the drug's patents have expired. It runs on a coverage-for-rebate bargain between the government and the manufacturer, not on generic competition. That makes it worth checking, for eligible patients, even while the underlying patent fight is still unresolved.

Some patients may already be paying less for a GLP-1 without realizing why, if they happen to receive care at a clinic that qualifies for 340B pricing, a program created by the Veterans Health Care Act of 1992. That law lets certain qualifying clinics and hospitals buy outpatient drugs at reduced prices, and some GLP-1 patients can access those lower costs depending on where they receive care. Like the Medicaid rebate program, this discount is set by statute and does not depend on whether a drug's patent has lapsed. It offers no promise for patients outside the 340B system, but for those who qualify, it is worth asking a clinic directly whether they participate.

The compounding pharmacies making headlines did not appear outside the law. The FDA's authority to allow compounded versions of a drug during a shortage comes from the FDA Safety and Innovation Act of 2012, and that authority is exactly what allowed compounded GLP-1s to appear in the first place. That authority is tied to the shortage designation, so once the FDA determines a drug is no longer in shortage, the compounding option built on this law closes. That is a separate, temporary arrangement from the patent-based path described earlier, and it does not offer the same lasting price relief that generic or biosimilar competition can bring once it arrives.

None of these five laws will hand a patient a lower price on their own, but together they describe the full set of options available while waiting for GLP-1 patents to expire. For patients enrolled in Medicaid or receiving care at a 340B clinic, it may be worth checking whether either program applies now, rather than waiting on the patent clock. For everyone else, especially those on the newer, still-protected molecules, the more useful habit is tracking patent challenges and expiration dates directly, since that is the path most likely to bring a lasting price change. Talk with your doctor about what is realistic for your situation, since a prescription will still be required no matter which path eventually lowers your cost.

Key details

• FDCA 1938 built the premarket review system that later patent laws build upon.

• Durham-Humphrey 1951 made GLP-1s prescription-only, requiring a doctor's order.

• OBRA 1990 set Medicaid rebate rules, a separate discount path from patent-driven pricing.

• Veterans Health Care Act 1992 created 340B discounts that can lower costs at some clinics.

• FDASIA 2012 gave FDA authority over the shortage-era compounding option.

Originally published on GLP1Laws

The FDA's shortage-based permission for bulk compounded semaglutide and tirzepatide is ending, and with it, the legal basis that let telehealth platforms supply hundreds of thousands of patients through 503B outsourcing facilities. This did not happen because of a single new rule. It happened because five separate pieces of federal law, some nearly a century old, work together to define what "legal" compounded GLP-1 access even means. Understanding those pieces helps explain what is closing and what still remains open for patients.

That standard, set by the Federal Food, Drug, and Cosmetic Act of 1938, requires a drug to go through premarket review before it can carry FDA approval. Compounded medications, by design, sit outside that process. A compounding pharmacy or outsourcing facility does not submit its version of semaglutide or tirzepatide for the same review that Ozempic, Wegovy, or Zepbound underwent. This is not a loophole or an oversight. It is the structural reason compounded GLP-1s were never approved products in the first place, even during the years when they were legal to dispense.

That classification came from the Durham-Humphrey Amendment of 1951, which split drugs into prescription and over-the-counter categories and required a licensed practitioner's involvement for the former. That framework is what makes patient-specific compounding possible at all under section 503A: a pharmacist can only prepare an individualized formulation in response to a valid prescription tied to a real patient's documented need. Without that 1951 line between prescription and non-prescription drugs, there would be no legal foundation for the 503A pathway that remains open even as the 503B bulk route closes. It is a narrower path than bulk compounding, built one prescription at a time, but it rests on law that predates the GLP-1 shortage by more than seventy years.

That deal, created by the Omnibus Budget Reconciliation Act of 1990, set up the Medicaid Drug Rebate Program, in which manufacturers agree to rebate a portion of the price back to Medicaid in exchange for their drugs being covered. That arrangement matters here because it shapes what happens to patients who lose access to compounded versions. Coverage for the FDA-approved products, the ones Medicaid rebate agreements apply to, does not automatically extend to compounded alternatives, since compounded drugs sit outside the approval and rebate structure altogether. For patients relying on Medicaid, the end of compounded access does not open a new coverage door. It shifts the question back to whether the approved product itself is covered and affordable under the existing rebate arrangement.

That law, the Veterans Health Care Act of 1992, created the 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs at a discount to certain safety-net providers and covered entities. Some patients losing access to compounded GLP-1s may find that a 340B-eligible clinic or health center offers a path to the approved product at a lower price than they would otherwise pay. This is not a universal fix, since 340B pricing depends on where a patient gets care and whether that provider qualifies as a covered entity. Still, for patients facing the closing compounded market, it is one of the few federally established discount mechanisms worth asking about.

That authority, granted under the FDA Safety and Innovation Act of 2012, gave the FDA formal power to track and declare drug shortages, and it is the same authority that opened the 503B bulk-compounding door for semaglutide and tirzepatide in 2022. The law works in both directions: it can open access when a shortage is declared, and it withdraws that access once the shortage is resolved. That is exactly what is happening now, as the FDA moves to exclude these drugs from the 503B bulks list because the clinical justification tied to the shortage no longer exists. The 2012 law was never a permanent grant of compounding rights. It was always a shortage-contingent one, and the current proposed rule is that contingency working exactly as written.

None of these laws were written with GLP-1 drugs in mind, yet together they explain both why compounded access existed and why it is ending. If you currently rely on a compounded semaglutide or tirzepatide product, the practical step is to talk with your prescriber now about what an FDA-approved alternative would look like for you, including whether a 340B-eligible provider or your existing coverage changes that calculation. Waiting until the rule is finalized and the supply disappears leaves fewer options and less time to sort out coverage or dosing. This is a legal and supply question, not a medical one, but it is worth planning for before the shortage-era arrangement fully closes.

Key details

• The 1938 law's approval standard is why compounded GLP-1s aren't FDA-approved.

• A 1951 amendment's prescription classification underlies the 503A patient pathway.

• Medicaid's 1990 rebate deal shapes coverage options if compounding access ends.

• Veterans law from 1992 created the 340B discount path some patients may rely on.

• FDASIA's 2012 shortage authority is the mechanism now closing GLP-1 compounding.

Originally published on GLP1Laws

Two people can hold the identical prescription and receive opposite answers about coverage, simply because they live in different states. That outcome is not an accident of modern politics. It traces back through decades of federal law, each piece adding another layer to how drugs reach pharmacies, who can prescribe them, and who decides whether an insurer has to pay. Understanding that history helps explain why your ZIP code, not just your diagnosis, so often decides your access to a GLP-1.

Before any GLP-1 could reach a pharmacy shelf, it had to clear a review process that did not exist before 1938. The Federal Food, Drug, and Cosmetic Act created the requirement that the FDA examine a drug's safety before it enters the market, and that same requirement still governs every GLP-1 sold today. This is a baseline that applies everywhere: no state, insurer, or employer gets to decide whether the drug is safe enough to exist, because federal law settled that question long ago. What varies by state, as later law makes clear, is a narrower question: whether someone will pay for it once it has been approved.

Thirteen years later, the Durham-Humphrey Amendment changed how a patient could obtain a GLP-1 at all. The 1951 law established that certain drugs, including what would become GLP-1s, could only be dispensed with a physician's prescription. That requirement means a doctor's diagnosis, not just a patient's request, determines whether a prescription can be written in the first place. It also means the diagnosis code attached to that prescription, whether it lists diabetes, cardiovascular risk, or obesity, becomes the detail that insurers and state programs later use to decide whether they will cover the drug.

The 1990 Omnibus Budget Reconciliation Act set up the Medicaid Drug Rebate Program, and this is the law most directly responsible for the state-by-state coverage differences patients see today. The program works as a bargain: drug manufacturers offer rebates to state Medicaid programs, and in exchange, states gain broad discretion over which drugs their Medicaid programs will cover, including for which indications. That discretion is why a minority of states currently cover GLP-1s for weight loss through Medicaid while most do not. It is also why a state can change its mind, as Massachusetts is doing by ending MassHealth coverage for weight-loss-only use in 2026 while keeping coverage for diabetes and other approved indications. The rebate program does not tell any state what to decide. It simply hands the decision to each state and lets the outcomes diverge.

Two years later, the Veterans Health Care Act of 1992 created the 340B Drug Pricing Program, which lets certain safety-net providers, such as community health centers and hospitals serving low-income populations, buy outpatient drugs at reduced prices. Where a GLP-1 is covered, the 340B program can lower the cost of getting it, but only at qualifying clinics. That means two patients with identical insurance coverage can still pay different amounts depending on whether the clinic filling their prescription participates in 340B. It also means the address of your clinic, separate from the address of your state, can affect what you pay.

By 2012, Congress recognized that coverage decisions mean little if the drug itself is not available, so the FDA Safety and Innovation Act gave the FDA formal authority to manage drug shortages. Under this law, the FDA can require manufacturers to report anticipated supply disruptions and can work to prevent or shorten shortages once they start. GLP-1 demand has strained manufacturing capacity in recent years, and this authority is part of what determines whether a covered prescription can actually be filled on a given week. Coverage and supply are separate problems, and this 2012 law addresses the second one, not the first.

None of these laws was written with today's obesity-drug debate in mind, yet together they explain why coverage looks so uneven from one state, one clinic, and one diagnosis to the next. If you are trying to get a GLP-1 covered, the practical response is to check the specific layer that applies to you: your state's Medicaid rules if you rely on that program, your plan's formulary if you have marketplace or employer coverage, whether your clinic participates in 340B if cost is the barrier, and whether a shortage is affecting your particular medication. Each of those checks answers a different question, and no single one of them will give you the whole picture on its own. Knowing which law governs which piece of your situation is what turns a frustrating patchwork into something you can actually work through.

Key details

• The 1938 FDCA required FDA safety review before your GLP-1 could reach pharmacies.

• The 1951 Durham-Humphrey Amendment made your GLP-1 a prescription-only drug.

• OBRA 1990's rebate program lets your state Medicaid decide GLP-1 obesity coverage.

• The 1992 Veterans Health Care Act's 340B program can cut GLP-1 costs at some clinics.

• FDASIA 2012 gave the FDA power to manage drug shortages affecting GLP-1 supply.

Originally published on GLP1Laws

Pharmacy benefit managers are the middlemen who decide what your insurance actually pays for a GLP-1 prescription, and this year several states are writing new rules for them. Missouri, New Jersey, and Florida each have bills in motion that touch different parts of that system, from audits to compounding rules to copay assistance. None of these bills has drawn much national attention. But if you fill a GLP-1 prescription in one of these states, the outcome could change what you pay or where you can fill it.

Missouri's SB 984 rewrites the rules PBMs use to audit independent pharmacies, and it caps how often those audits can happen. It also bars contracts that let a PBM charge a patient more at the pharmacy counter than that patient would pay in cash. The bill adds a program aimed at keeping critical access pharmacies open, which matters because those are often the pharmacies serving rural GLP-1 patients. Right now the bill sits on the Senate's informal calendar, waiting for a vote to move it toward the House. If you fill a GLP-1 prescription at an independent pharmacy in Missouri, this bill affects whether that pharmacy stays in business long enough to keep filling it.

New Jersey has two bills moving through its legislature that would tighten what pharmacy boards allow when it comes to compounded GLP-1 preparations. Both bills are classified as restrictive, and they arrive at a moment when the legal status of compounded GLP-1s is already unsettled, since these drugs were recently removed from the FDA's shortage list. That removal changed what pharmacies are allowed to compound in the first place, so New Jersey's bills add a second layer of state-level restriction on top of a federal shift. These bills are moving more slowly than Missouri's, but they are active, and anyone relying on a compounded GLP-1 in New Jersey should keep an eye on them.

Florida's SB 228 would have required insurers and PBMs to count a patient's copay assistance, including manufacturer coupons, toward that patient's actual out-of-pocket maximum. It died in committee in 2024 without reaching a floor vote. That defeat matters beyond Florida, because it showed opponents of copay accumulator bans where and how to stop similar bills before they advance. The idea behind SB 228 has not disappeared, and there is reason to expect it to reappear in Florida's 2026 session. Patients who rely on manufacturer copay assistance for a GLP-1 prescription are the ones this bill was written to protect, and its failure kept that protection out of reach for another cycle.

The same copay accumulator idea that failed in Florida is not confined to Florida. Similar bills are already queued in at least four other states, each proposing to require insurers to count copay assistance toward a patient's deductible or out-of-pocket maximum. That repetition suggests this is less a single-state fight and more a pattern playing out across several legislatures at once. Patients in those states will want to check whether their state is one of the four, since the outcome there will shape whether copay assistance actually lowers what they pay at the pharmacy counter.

Florida also introduced SB 1342, which would have required insurers to give notice before changing a drug's formulary status, and SB 1608, which addressed protections tied to the 340B drug pricing program. Both bills died without ever getting the committee hearing they needed to move forward. Each one addressed a real access problem, from formulary changes that catch patients off guard to pricing protections that hospitals and clinics depend on, but neither made it far enough in the process to reach a vote. Their failure means those specific gaps in Florida's drug pricing rules remain open for now.

If any of these bills is moving in your state, you are not just a bystander in this process. State legislators take calls from constituents, and sponsor names are listed on every bill page for exactly that reason. Committee chairs decide which bills get a hearing and which never move at all, so if you want to see a bill advance, that is who to contact. Watching bill numbers is useful, but reaching out is what actually changes whether these votes happen.

Key details

• Missouri's SB 984 caps PBM audits and bars overcharging patients at independent…

• New Jersey has two bills that would limit compounded GLP-1 preparations through pharmacy…

• Florida's SB 228, a copay accumulator ban, died in 2024 but may return in 2026.

• Similar copay accumulator bans are already queued in at least four other states.

• Florida's SB 1342 and SB 1608, on formulary transparency and 340B, both died without a…

Originally published on GLP1Laws